|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, xenograft tumors induced by A549/DDP cells exerted cisplatin resistance, and miR-186-5p overexpression could inhibit tumor growth under DDP treatment.
|
31686523 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Further assays demonstrated that miR-186-5p overexpression had inhibitory effects on in-vitro cell proliferation, cell cycle, and in-vivo tumor growth. miR-186-5p overexpression also inhibited the epithelial-tomesenchymal transition (EMT), migration and invasion of OS cells.
|
30897321 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings suggest that miR-186 functions as a tumor suppressor by targeting Twist1 in BC. miR-186 may serve as a novel biomarker in BC diagnosis or a new therapeutic target in BC treatment.
|
30552711 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Restoration of miR-186 levels in neuroblastoma through NK cell-derived exosomes or by nanoparticle delivery reduces tumor burden, promotes survival, and restores the cell-killing abilities of NK cells, demonstrating the therapeutic potential of tumor-suppressive miRNAs in neuroblastoma.<i>See related article by Neviani and colleagues; Cancer Res 79(6):1151-64</i>.
|
30936073 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the present study, the expression of miR-186 was significantly increased in CSCC tissues compared with adjacent non-tumour tissues.
|
30867688 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Altogether, these data support the investigation of a miR-186-containing nanoparticle formulation to prevent tumor growth and TGFβ1-dependent immune escape in high-risk neuroblastoma patients as well as the inclusion of <i>ex vivo</i>-derived NK exosomes as a potential therapeutic option alongside NK cell-based immunotherapy.<b>Significance:</b> These findings highlight the therapeutic potential of NK cell-derived exosomes containing the tumor suppressor miR-186 that inhibits growth, spreading, and TGFβ-dependent immune escape mechanisms in neuroblastoma.
|
30541743 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, our data revealed that HIF-1α was a downstream target of miR-186-5p and that NEAT1 could exert its tumor oncogenic roles on OS cells via the miR-186-5p/HIF-1α axis.
|
30485482 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In a word, our study found that miR-186-5p could inhibit tumor proliferation by targeting Eg5 in neuroblastoma.
|
31105832 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
By inhibiting the proliferation of myeloma cells, miR-186 gene and ZNF protein may be used as tumor suppressors in the treatment of myeloma.
|
31165610 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression level of miR-186 was downregulated in cervical cancer tumors and cell lines and was negatively correlated to that of ANRIL.
|
28550682 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data demonstrated that miR-186 acted as a novel tumor suppressor and potential therapeutic biomarker in the progression of RCC by directly targeting SENP1.
|
28550686 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-186 serves as a tumor suppressor in oral squamous cell carcinoma by negatively regulating the protein tyrosine phosphatase SHP2 expression.
|
29407635 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-186 promotes tumor growth in cutaneous squamous cell carcinoma by inhibiting apoptotic protease activating factor-1.
|
30344679 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Bioinformatic predictions, a luciferase reporter assay, and protein expression analysis suggested that miR-186 could inhibit the protein levels of SIRT6, a purported tumor suppressor gene.
|
29125477 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These results indicated the tumor‑suppressive role of miR‑186 in OS.
|
29693191 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The miR-186-5p expression promotes colorectal cancer pathogenesis by regulating tumour suppressor FAM134B.
|
28549913 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Xenograft tumor animal model was established to elucidate the in vivo function of miR-186-5p.
|
28213656 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
When miR-186 overexpressed in PCa cells, cell proliferation <i>in vitro</i> was evidently inhibited as shown using cell counting kit-8 assays and cell-cycle analysis, and tumor growth <i>in vivo</i> was decreased as shown by tumor growth assays in nude mice.
|
28587405 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MicroRNA-186 affects the proliferation of tumor cells via yes-associated protein 1 in the occurrence and development of pancreatic cancer.
|
28962129 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These findings demonstrated that miR‑186 acted as a tumor suppressor by targeting IGF‑1R in glioma, suggesting miR‑186 may be a potential therapeutic target for the treatment of this disease.
|
28944896 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The present study aimed to identify the miRNAs that perform a role in GIST metastasis. miRNA expression profiles from a series of 32 primary GISTs were analyzed using microarrays, and miR-186 was observed to be downregulated in tumors exhibiting metastatic recurrence.
|
29113198 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The present study aimed to investigate the expression of microRNA (miRNA or miR)-186 in tumor tissue, blood and urine from patients with bladder cancer.
|
28966690 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The miR-186 mimic enhanced the tumor growth inhibitory effects of paclitaxel in A549 xenografts.
|
27714074 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our collective results clearly indicate that miR-186 functions as a tumor suppressor in MM, supporting its potential as a therapeutic target for the disease.
|
26679605 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, miR-186 and Twist1 were associated with larger tumor size and advanced clinical stage of GC.
|
27835599 |
2016 |